

2010 - 2013 Performance Measures

<u>BCS</u>	<u>HRH</u>	<u>CoC St/%</u>
2010	86%	n/a
2011	69%	
2012	96%	
2013	90%	
<b>nBx</b>		
2010	85%	80%
2011	97%	
2012	98%	
2013	92%	
<b>Mast RT</b>		
		90%
2010	100%	
2011	100%	
2012	100%	
2013	100%	
<b>BCS RT</b>		
		90%
2010	100%	
2011	100%	
2012	96%	
2013	94%	
<b>MAC</b>		
		n/a
2010	100%	
2011	100%	
2012	100%	
2013	100%	
<b>HT</b>		
		90%
2010	95%	
2011	100%	
2012	96%	
2013	87%	

<u>ACT</u>	<u>HRH</u>	<u>CoC St/%</u>
2010	100%	90%
2011	100%	
2012	100%	
2013	100%	
<b>12RLN</b>		
2010	89%	85%
2011	82%	
2012	93%	
2013	100%	

<u>Rec RT</u>	<u>HRH</u>	<u>CoC St/%</u>
2010	100%	85.00%
2011	100%	
2012	100%	
2013	100%	

<u>G15 RLN</u>	<u>HRH</u>	<u>CoC St/%</u>
2010	no data	n/a
2011	no data	
2012	no data	
2013	no data	

<u>OVSAL</u>	<u>HRH</u>	<u>CoC St/%</u>
2010	0%	n/a
2011	0%	
2012	0%	
2013	no data	

<u>Endometrium</u>	<u>HRH</u>	<u>CoC St/%</u>
<b>ENDCTRT</b>		
		n/a
2010	100%	
2011	no data	
2012	no data	
2013	no data	
<b>ENDLRC</b>		
2010	33%	
2011	0%	
2012	100%	
2013	no data	

<u>10 RLN</u>	<u>HRH</u>	<u>CoC St/%</u>
2010	0%	n/a
2011	0%	
2012	0%	
2013	0%	
<b>LCT</b>		
		n/a
2010	100%	
2011	100%	
2012	no data	
2013	100%	
<b>LNoSurg</b>		
		85.00%
2010	100%	
2011	100%	
2012	100%	
2013	100%	

<u>CERRT</u>	<u>HRH</u>	<u>CoC St/%</u>
		n/a

## 2010 - 2013 Performance Measures

2010	100%	
2011	no data	
2012	100%	
2013	100%	
<b><u>CERCT</u></b>		n/a
2010	100%	
2011	no data	
2012	50%	
2013	100%	
<b><u>CBRRT</u></b>		n/a
2010	100%	
2011	no data	
2012	no data	
2013	no data	

## 2010 - 2013 Performance Measures

- Breast** Breast conservation surgery rate for women w/AJCC clinical stage 0,1,2 breast cancer (Surveillance) **BCS**  
Image or palpation guided needle (core or FNA) is performed to establish diagnosis of breast ca (Quality Improvement) **nBx**  
Radiation therapy is considered or administered following any mastectomy within 1 year (365 days) of diagnosis of breast ca for women with  $\geq 4$  + regional LN  
Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer. (Account Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1c N0 M0, or Stage II or III I Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1c N0 M0, or Stage
- Colon** Adjuvant chemotherapy is considered or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer. **[12RLN]**
- Rectum** Radiation therapy is considered or administered within 6 months (180 days) of diagnosis for patients under the age of 80 of with clinical or pathologic AJCC T4N0
- Gastric** At least 15 regional LN are removed and pathologically examined for resected gastric cancer **G15RLN**
- Lung** at least 10 regional lymph nodes are removed and pathologically examined for AJCC stage 1a, 1b, 2a, and 2b resected NSCLC (Surveillance) **10 RLN**  
Systemic chemotherapy is administered within 4 months to day preoperatively or day of surgery to 6 months postoperatively, or it is considered for surgically resected lung cancer if surgery is not the first course of treatment for cN2, M0 lung cases (Quality Improvement) **LNoSurg**
- Cervix** Radiation Therapy completed within 60 days of initiation of radiation among women diagnosed with any stage of cervical cancer (Surveillance) **CERRT**  
Chemotherapy administered to cervical cancer patients who received radiation for stages 1B2-IV cancer (Group 1) of with positive pelvic nodes, positive surgical margin, and/or positive para-aortic nodes (Quality Improvement) **CBRR**  
Use of brachtherapy in patients treated with primary radiation with curative intent in any stage of cervical cancer (Surveillance) **CBRR**
- Endometriun** Chemotherapy and/or radiation administered to patients with Stage 3C or IV Endometrial Cancer (Surveillance) **ENDCTR**  
Endoscopic, laparoscopic, or robotic performed for all endometrial cancer (excluding sarcoma and lymphoma) for all stages except Stage IV (Surveillance) **ENDLRC**
- Ovary** Salpingo-oophorectomy with omentectomy, debulking, /cytoreductive surgery or pelvic exenteration in Stages 1-3C ovarian cancer (Surveillance) **OVSA**

2010 - 2013 Performance Measures

## 2010 - 2013 Performance Measures

N (Accountability) **Mast RT**

ability) **[BCS/RT]**

ERA and PRA negative breast cancer. **[MAC]**

: II or III ERA and/or PRA positive breast cancer. **[HT]**

: positive) colon cancer. **[ACT]**

DM0 or Stage III receiving surgical resection for rectal cancer. **[REC RT]**

ected cases with pathology lymph node-positive (pN1) and pN2) NSCLC (Quality Improvement) **LCT**

rametrium (Group 2) (Surveillance) **CERRCT**